⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885049 | 0.81 | — | — | |
| SCHEMBL13086010 | 0.77 | — | — | |
| SCHEMBL15817287 | 0.75 | — | — | |
| SCHEMBL29431211 | 0.75 | — | — | |
| SCHEMBL21240970 | 0.75 | — | — | |
| SCHEMBL537945 | 0.75 | — | — | |
| SCHEMBL15203394 | 0.75 | — | — | |
| SCHEMBL29781624 | 0.75 | — | — | |
| SCHEMBL2067650 | 0.71 | — | — | |
| SCHEMBL13349290 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264278-A1 | ERK2 DEGRADERS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-114516856-B | Dihydro-isoquinolinone and isoindolinone derivatives and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250145624-A1 | MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2025-05-08 | — | — | US | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118974048-A | Membrane-associated tyrosine and threonine-specific CDC2 inhibitor kinase (PKMYT 1) inhibitors and uses thereof | 英矽智能科技知识产权有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118930534-A | Indazole-containing compound, pharmaceutical composition, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024104398-A1 | PYRIDINE NITROGEN OXIDE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2024-05-23 | — | — | WO | disclosed |
| CN-118047757-A | Pyridine nitrogen oxide derivative, pharmaceutical composition, preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-114516856-A | Dihydroisoquinolinone and isoindolinone derivatives and uses thereof | 中国科学院合肥物质科学研究院 | 2022-05-20 | — | — | CN | disclosed |
| EP-3967695-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2022-03-16 | — | — | EP | disclosed |
| CN-109906224-B | Triazolopyridine compounds and uses thereof | 诺华股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113748114-A | Quinazoline compound and application thereof in medicine | 贝达药业股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2020216190-A1 | QUINAZOLINE COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF | 贝达药业股份有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-10689378-B2 | Triazolopyridine compounds and uses thereof | NOVARTIS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3472161-B1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-20190202828-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-07-04 | — | — | US | disclosed |
| EP-3472161-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221092-A1 | TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2017-12-28 | — | — | WO | disclosed |